UNC Chapel Hill Gene Therapy Center spinout developing GENV HEM, a universal gene therapy for all types of hemophilia (including patients with inhibitors to clotting factors); pipeline expanded to include a Pompe disease program in 2025.
At a glance
- HQ: Chapel Hill
- Sector: Biotech
- Stage: Pre Seed
- Affiliation: UNC
This is the free preview.
The full profile is for members: founders, funding history, investor connections, and recent signals. Accounts are free; I review every request, usually within 48 hours.